119 related articles for article (PubMed ID: 1723893)
1. CSF chromogranin A-like immunoreactivity in schizophrenia. Assessment of clinical and biochemical relationships.
van Kammen DP; Peters J; Yao J; Neylan T; Beuger M; Pontius E; O'Connor DT
Schizophr Res; 1991 Dec; 6(1):31-9. PubMed ID: 1723893
[TBL] [Abstract][Full Text] [Related]
2. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
van Kammen DP; Agren H; Yao JK; O'Connor DT; Gurklis J; Peters JL
Am J Psychiatry; 1994 Mar; 151(3):379-84. PubMed ID: 7509126
[TBL] [Abstract][Full Text] [Related]
3. CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
van Kammen DP; Peters J; van Kammen WB; Nugent A; Goetz KL; Yao J; Linnoila M
Biol Psychiatry; 1989 Jun; 26(2):176-88. PubMed ID: 2472177
[TBL] [Abstract][Full Text] [Related]
4. CSF chromogranin A-like immunoreactivity in schizophrenia: relationships with REM latency and slow wave sleep.
van Kammen DP; O'Connor DT; Neylan TC; Mouton A; Gurklis JA; Gilbertson MW; Peters JL
Psychiatry Res; 1992 Apr; 42(1):53-63. PubMed ID: 1603881
[TBL] [Abstract][Full Text] [Related]
5. Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited.
van Kammen DP; Peters J; Yao J; van Kammen WB; Neylan T; Shaw D; Linnoila M
Arch Gen Psychiatry; 1990 Feb; 47(2):161-8. PubMed ID: 1689140
[TBL] [Abstract][Full Text] [Related]
6. Neuropeptide Y-like immunoreactivity in schizophrenia. Relationships with clinical measures.
Peters J; Van Kammen DP; Gelernter J; Yao J; Shaw D
Schizophr Res; 1990; 3(5-6):287-94. PubMed ID: 2178001
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.
Pickar D; Breier A; Hsiao JK; Doran AR; Wolkowitz OM; Pato CN; Konicki PE; Potter WZ
Arch Gen Psychiatry; 1990 Jul; 47(7):641-8. PubMed ID: 1694425
[TBL] [Abstract][Full Text] [Related]
8. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.
Breslin NA; Suddath RL; Bissette G; Nemeroff CB; Lowrimore P; Weinberger DR
Schizophr Res; 1994 Apr; 12(1):35-41. PubMed ID: 7517175
[TBL] [Abstract][Full Text] [Related]
9. Reliability of norepinephrine and major monoamine metabolite measurements in CSF of schizophrenic patients.
Linnoila M; Ninan PT; Scheinin M; Waters RN; Chang WH; Bartko J; van Kammen DP
Arch Gen Psychiatry; 1983 Dec; 40(12):1290-4. PubMed ID: 6197036
[TBL] [Abstract][Full Text] [Related]
10. CSF diazepam binding inhibitor and schizophrenia: clinical and biochemical relationships.
van Kammen DP; Guidotti A; Kelley ME; Gurklis J; Guarneri P; Gilbertson MW; Yao JK; Peters J; Costa E
Biol Psychiatry; 1993 Oct; 34(8):515-22. PubMed ID: 8274578
[TBL] [Abstract][Full Text] [Related]
11. Clonidine treatment of schizophrenia: can we predict treatment response?
van Kammen DP; Peters JL; van Kammen WB; Rosen J; Yao JK; McAdam D; Linnoila M
Psychiatry Res; 1989 Mar; 27(3):297-311. PubMed ID: 2469097
[TBL] [Abstract][Full Text] [Related]
12. Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia.
van Kammen DP; Kelley ME; Gurklis JA; Gilbertson MW; Yao JK; Peters JL
Arch Gen Psychiatry; 1995 Aug; 52(8):673-8. PubMed ID: 7543265
[TBL] [Abstract][Full Text] [Related]
13. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.
Hsiao JK; Colison J; Bartko JJ; Doran AR; Konicki PE; Potter WZ; Pickar D
Arch Gen Psychiatry; 1993 Aug; 50(8):606-14. PubMed ID: 7688209
[TBL] [Abstract][Full Text] [Related]
14. Aberrant monoamine metabolite levels in CSF and family history of schizophrenia. Their relationships in schizophrenic patients.
Sedvall GC; Wode-Helgodt B
Arch Gen Psychiatry; 1980 Oct; 37(10):1113-6. PubMed ID: 6158928
[TBL] [Abstract][Full Text] [Related]
15. Atrophy limited to the third ventricle in chronic schizophrenic patients. Report of a controlled series.
Boronow J; Pickar D; Ninan PT; Roy A; Hommer D; Linnoila M; Paul SM
Arch Gen Psychiatry; 1985 Mar; 42(3):266-71. PubMed ID: 2579616
[TBL] [Abstract][Full Text] [Related]
16. CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide.
Roy A; Ninan P; Mazonson A; Pickar D; Van Kammen D; Linnoila M; Paul SM
Psychol Med; 1985 May; 15(2):335-40. PubMed ID: 2410941
[TBL] [Abstract][Full Text] [Related]
17. The relationship between clinical and biochemical changes following neuroleptic treatment in schizophrenia.
Cooper SJ; Leahey W; Liddle J; King DJ
Schizophr Res; 1990; 3(4):261-7. PubMed ID: 1703780
[TBL] [Abstract][Full Text] [Related]
18. Melperone in the treatment of schizophrenia.
Bjerkenstedt L
Acta Psychiatr Scand Suppl; 1989; 352():35-9. PubMed ID: 2479227
[TBL] [Abstract][Full Text] [Related]
19. Monoamine metabolite levels in cerebrospinal fluid and brain atrophy in lobotomized schizophrenic patients.
Rimón R; Roos BE; Kampman R; Hyyppä S; Ranta P; Myllylä V
Ann Clin Res; 1979 Feb; 11(1):25-9. PubMed ID: 453776
[TBL] [Abstract][Full Text] [Related]
20. CSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin).
Miller C; Kirchmair R; Troger J; Saria A; Fleischhacker WW; Fischer-Colbrie R; Benzer A; Winkler H
Biol Psychiatry; 1996 Jun; 39(11):911-8. PubMed ID: 9162202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
